Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Titre (en) » - entrée « receptor »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
recently < receptor < receptors  Facettes :

List of bibliographic references indexed by receptor

Number of relevant bibliographic references: 382.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000010 (2020) Aline Pfefferle [Australie] ; Nicholas D. Huntington [Australie]You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
000031 (2020) Jerome Razanamahery [France] ; Sebastien Humbert [France] ; Helder Gil [France] ; Kevin Bouiller [France] ; Nadine Magy-Bertrand [France]Tropheryma Whipplei infection mimicking giant cell arteritis flare in a patient treated with interleukin-6 receptor blocker tocilizumab.
000035 (2020) Limin Li [République populaire de Chine] ; Jie Liu [République populaire de Chine] ; Mengyuan Xu [République populaire de Chine] ; Hongjuan Yu [République populaire de Chine] ; Chengfang Lv [République populaire de Chine] ; Fenglin Cao [République populaire de Chine] ; Zhenkun Wang [République populaire de Chine] ; Yueyue Fu [République populaire de Chine] ; Mingwen Zhang [République populaire de Chine] ; Hongbin Meng [République populaire de Chine] ; Xiaoqian Zhang [République populaire de Chine] ; Liqing Kang [République populaire de Chine] ; Zhuo Zhang [République populaire de Chine] ; Jinmei Li [République populaire de Chine] ; Jiawei Feng [République populaire de Chine] ; Xin Lian [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Jin Zhou [République populaire de Chine]Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients
000052 (2020) Yasuhiko Hirabayashi [Japon]Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis.
000053 (2020) Jean-Marie Michot [France] ; Laurence Albiges [France] ; Nathalie Chaput [France] ; Veronique Saada [France] ; Fanny Pommeret [France] ; Franck Griscelli [France] ; Corinne Balleyguier [France] ; Benjamin Besse [France] ; Aurélien Marabelle [France] ; Florence Netzer [France] ; Mansouria Merad [France] ; Caroline Robert [France] ; Fabrice Barlesi [France] ; Bertrand Gachot [France] ; Annabelle Stoclin [France]Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
000076 (2020) Philip George [Nouvelle-Zélande] ; Nathaniel Dasyam [Nouvelle-Zélande] ; Giulia Giunti [Nouvelle-Zélande] ; Brigitta Mester [Nouvelle-Zélande] ; Evelyn Bauer [Nouvelle-Zélande] ; Bethany Andrews [Nouvelle-Zélande] ; Travis Perera [Nouvelle-Zélande] ; Tess Ostapowicz [Nouvelle-Zélande] ; Chris Frampton [Nouvelle-Zélande] ; Peng Li [République populaire de Chine] ; David Ritchie [Australie] ; Catherine M. Bollard [États-Unis] ; Ian F. Hermans [Nouvelle-Zélande] ; Robert Weinkove [Nouvelle-Zélande]Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
000095 (2020) Chi Zhang [République populaire de Chine] ; Zhao Wu [République populaire de Chine] ; Jia-Wen Li [République populaire de Chine] ; Hong Zhao [République populaire de Chine] ; Gui-Qiang Wang [République populaire de Chine]The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
000121 (2020) Mattia Rosso [États-Unis] ; Shrishti Saxena [États-Unis] ; Tanuja Chitnis [États-Unis]Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
000130 (2020) Gang Heng [République populaire de Chine] ; Jiankun Jia [République populaire de Chine] ; Shiqi Li [République populaire de Chine] ; Gang Fu [République populaire de Chine] ; Meiling Wang [République populaire de Chine] ; Dabing Qin [République populaire de Chine] ; Yunyan Li [République populaire de Chine] ; Li Pei [République populaire de Chine] ; Xiaobo Tian [République populaire de Chine] ; Jiasi Zhang [République populaire de Chine] ; Yi Wu [République populaire de Chine] ; Shali Xiang [République populaire de Chine] ; Jia Wan [République populaire de Chine] ; Wei Zhu [République populaire de Chine] ; Pei Zhang [République populaire de Chine] ; Qianzhen Zhang [République populaire de Chine] ; Xi Peng [République populaire de Chine] ; Linling Wang [République populaire de Chine] ; Ping Wang [République populaire de Chine] ; Zhihao Wei [République populaire de Chine] ; Yingzi Zhang [République populaire de Chine] ; Guiqin Wang [République populaire de Chine] ; Xue Chen [République populaire de Chine] ; Chengcheng Zhang [République populaire de Chine] ; Yanni Sun [République populaire de Chine] ; Wenxu Zhao [République populaire de Chine] ; Yahan Fan [République populaire de Chine] ; Zhi Yang [République populaire de Chine] ; Jieping Chen [République populaire de Chine] ; Cheng Qian [République populaire de Chine]Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.
000138 (2020) Hao Zhang ; Yongxian HuSuccessful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
000155 (2020) Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui YangSevere sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000157 (2020) Jingsheng Hua [République populaire de Chine] ; Weiqing Qian [République populaire de Chine] ; Xiaoxia Wu [République populaire de Chine] ; Lili Zhou [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Suning Chen [République populaire de Chine] ; Jian Zhang [République populaire de Chine] ; Huiying Qiu [République populaire de Chine]Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
000256 (2020) Francesco Bennardo [Italie] ; Caterina Buffone [Italie] ; Amerigo Giudice [Italie]New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.
000264 (2020) Domenico Acanfora [Italie] ; Marco Matteo Ciccone [Italie] ; Pietro Scicchitano [Italie] ; Chiara Acanfora [Italie] ; Gerardo Casucci [Italie]Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
000271 (2020) Gabriella Bottari [Italie] ; Pietro Merli [Italie] ; Isabella Guzzo [Italie] ; Francesca Stoppa [Italie] ; Annalisa Ruggeri [Italie] ; Matteo Di Nardo [Italie] ; Francesca Del Bufalo [Italie] ; Federica Galaverna [Italie] ; Cecchetti Corrado [Italie] ; Franco Locatelli [Italie]Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion
000289 (2020) Ibrahim Yakoub-Agha [France] ; Christian Chabannon [France] ; Peter Bader [Allemagne] ; Grzegorz W. Basak [Pologne] ; Halvard Bonig [Allemagne] ; Fabio Ciceri [Italie] ; Selim Corbacioglu [Allemagne] ; Rafael F. Duarte [Espagne] ; Hermann Einsele [Allemagne] ; Michael Hudecek [Allemagne] ; Marie José Kersten [Pays-Bas] ; Ulrike Köhl [Allemagne] ; Jürgen Kuball [Pays-Bas] ; Stephan Mielke [Suède] ; Mohamad Mohty [France] ; John Murray [Royaume-Uni] ; Arnon Nagler [Israël] ; Stephen Robinson [Royaume-Uni] ; Riccardo Saccardi [Italie] ; Fermin Sanchez-Guijo [Espagne] ; John A. Snowden [Royaume-Uni] ; Micha Srour [France] ; Jan Styczynski [Pologne] ; Alvaro Urbano-Ispizua [Espagne] ; Patrick J. Hayden [Irlande (pays)] ; Nicolaus Kröger [Allemagne]Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
000310 (2020) Guoqiang Zhang [République populaire de Chine] ; Hayato Iwase [États-Unis] ; Liaoran Wang [États-Unis] ; Takayuki Yamamoto [États-Unis] ; Abhijit Jagdale [États-Unis] ; David Ayares [États-Unis] ; Yong Li [République populaire de Chine] ; David K C. Cooper [États-Unis] ; Hidetaka Hara [États-Unis]Is interleukin-6 receptor blockade (tocilizumab) beneficial or detrimental to pig-to-baboon organ xenotransplantation?
000313 (2020) François Santinon [France] ; Maxime Batignes [France] ; Majda Lyna Mebrek [France] ; Jerôme Biton [France] ; Gaëlle Clavel [France] ; Roxane Hervé [France] ; Delphine Lemeiter [France] ; Magali Breckler [France] ; Florence Busato [France] ; Jorg Tost [France] ; Marianne Ziol [France] ; Marie-Christophe Boissier [France] ; Patrice Decker [France] ; Luca Semerano [France] ; Natacha Bessis [France]Involvement of Tumor Necrosis Factor Receptor Type II in FoxP3 Stability and as a Marker of Treg Cells Specifically Expanded by Anti-Tumor Necrosis Factor Treatments in Rheumatoid Arthritis.
000350 (2020) Anna-Sophia Kattner ; Ernst Holler ; Barbara Holler ; Sebastian Klobuch ; Daniela Weber ; Danilo Martinovic ; Matthias Edinger ; Wolfgang Herr ; Daniel WolffIL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
000372 (2020) Michie Imamura ; Akihiro Mukaino ; Koutaro Takamatsu ; Hiroto Tsuboi ; Osamu Higuchi ; Hideki Nakamura ; Saori Abe ; Yukio Ando ; Hidenori Matsuo ; Tadashi Nakamura ; Takayuki Sumida ; Atsushi Kawakami ; Shunya NakaneGanglionic Acetylcholine Receptor Antibodies and Autonomic Dysfunction in Autoimmune Rheumatic Diseases
000389 (2020) Koichi Nakamura ; Tomoki Nakamura ; Takahiro Iino ; Tomohito Hagi ; Kouji Kita ; Kunihiro Asanuma ; Akihiro SudoExpression of Interleukin-6 and the Interleukin-6 Receptor Predicts the Clinical Outcomes of Patients with Soft Tissue Sarcomas

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "receptor" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "receptor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    receptor
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021